Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer
暂无分享,去创建一个
L. Carey | A. Bardia | K. Blackwell | T. Traina | M. Danso | H. Ali | N. Gabrail | J. Eisner | A. Gucalp | E. Baskin-Bey | N. DaCosta